Safety and Effectiveness of NXY-059 for the Treatment of Patients who have Suffered from a Stroke
Study identifier:SA-NXY-0006
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
SAINT I (Stroke – Acute Ischemic – NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke.
Medical condition
Cerebral Stroke
Phase
Phase 3
Healthy volunteers
No
Study drug
NXY-059
Sex
All
Actual Enrollment
1700
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jun 2003
Primary Completion Date: 01 Feb 2005
Study Completion Date: 01 Feb 2005
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca NXY-059 Medical Science Director
AstraZeneca
